Phase II studies in advanced, recurrent pelvic malignancies: Conducted by the Gynecologic Oncology Group Experimental Design and Experience

Abstract

In response to a nationwide need, the Gynecologic Oncology Group (GOG) designed and implemented a master protocol system for Phase II clinical studies in the treatment of advanced recurrent pelvic malignancies. Under this master protocol, eleven investigational anticancer drugs have been studied: Piperazinedione, cis-diamminedichloroplatinum, VP 16, dianhydrogalactitol, Baker's Antifol, ICRF 159, maytansine, AMSA, YOSHI 864, tamoxifen, and PALA. Experimental design and results on the investigational drugs studied under this protocol are presented and discussed.